Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy

Eur J Cancer. 2017 Apr:75:308-309. doi: 10.1016/j.ejca.2016.12.027. Epub 2017 Mar 1.

Authors

P Pradere¹, J M Michot², S Champiat², F X Danlos², A Marabelle², O Lambotte³, L Albiges⁴, J Le Pavec¹

Affiliations

¹ Thoracic Department, Marie Lannelongue Surgical Center, Le Plessis Robinson, 92350, France.
² Drug Development Department, Gustave Roussy Institute, Villejuif, 94805, France.
³ APHP, Internal Medicine and Clinical Immunology Department, Bicêtre Hospital, AP-HP, Le Kremlin Bicêtre, 94270, France; Université Paris Sud, 63 rue Gabriel Péri, 94276 Le Kremlin Bicêtre, France.
⁴ Medical Oncology Department, Gustave Roussy Institute, Villejuif, 94805, France.

PMID: 28259013
DOI: 10.1016/j.ejca.2016.12.027

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Aspergillosis, Allergic Bronchopulmonary / chemically induced*
Carcinoma, Renal Cell / drug therapy
Carcinoma, Renal Cell / pathology
Humans
Immunocompromised Host
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use
Indoles / therapeutic use
Kidney Neoplasms / drug therapy
Kidney Neoplasms / pathology
Lung Neoplasms / drug therapy
Lung Neoplasms / secondary
Male
Middle Aged
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology*
Pyrroles / therapeutic use
Sunitinib

Substances

Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
Indoles
Programmed Cell Death 1 Receptor
Pyrroles
Sunitinib